SME Times is powered by   
Search News
Just in:   • Crude oil prices surge over 3 pc over Iran tensions, Trump deadline  • Sensex, Nifty slide 1 pc as Hormuz deadline by US rattles markets  • Sensex, Nifty extend rally for 3rd day on hopes of US-Iran de-escalation  • Global energy flows disrupted by West Asia crisis: SEBI Chairman  • CAIT urges govt to implement credit relief, input cost stabilisation measures amid Iran war 
Last updated: 01 Feb, 2017  

cadila.thumb.jpg Cadila Healthcare net profit declines 34.6 pc in Q3

cadila.jpg
   Top Stories
» Sensex, Nifty slide 1 pc as Hormuz deadline by US rattles markets
» Sensex, Nifty extend rally for 3rd day on hopes of US-Iran de-escalation
» CAIT urges govt to implement credit relief, input cost stabilisation measures amid Iran war
» RBI MPC meet begins, status quo on policy rate likely amid West Asia tensions
» Govt launches programme to train scientists in Governance under Mission Karmayogi
SME Times News Bureau | 01 Feb, 2017
Global pharmaceutical company Cadila Healthcare on Tuesday posted a 34.6 percent decline in its consolidated net profit to Rs 281.6 crore for the quarter ended December 31, 2016 as compared with Rs 430.5 crore in the year-ago period.

The company's consolidated total income from operations also dipped to Rs 2,363.8 crore during the quarter under review as compared with Rs 2,408.9 crore in a year-ago period.

On BSE, the stock settled at Rs 349.25, down 7.02 percent from the previous close.
 
Print the Page Add to Favorite
 
Share this on :
 

Please comment on this story:
 
Subject :
Message:
(Maximum 1500 characters)  Characters left 1500
Your name:
 

 
  Customs Exchange Rates
Currency Import Export
US Dollar
₹94.25
₹92.55
UK Pound
₹125.95
₹121.95
Euro
₹108.95
₹105.3
Japanese Yen ₹59.4 ₹57.6
As on 02 Apr, 2026
  Daily Poll
What is the biggest war impact on MSMEs?
 Export Disruption
 Raw Material Spike
 Freight Cost Surge
 Payment Delays
 Currency Volatility
 All
  Commented Stories
 
 
About Us  |   Advertise with Us  
  Useful Links  |   Terms and Conditions  |   Disclaimer  |   Contact Us  
Follow Us : Facebook Twitter